Viral Based Therapeutics

Our facility in Houston, Texas houses the critical infrastructure, technology and expertise to safely and effectively manufacture your viral-based product.  The experienced viral team has been involved in the manufacture and release of over 60 batches of Phase I through Phase III clinical trial materials for use in the US, Europe and Japan.  Our clients value our extensive industry experience in process development, GMP manufacturing, product characterization and release and regulatory submission.  Lonza’s global reach, high-quality facilities, and technical capabilities allow us to be a trusted partner for your Viral Vaccine and Gene Therapy pipeline.

Wherever you are in your process, Lonza has been there too.  Currently we operate a state-of-the-art multi-product facility that utilizes current single-use disposable technology and meets the EU and US regulatory compliance standards for cGMP bulk production and fill/finish of viral products.  In addition, Lonza operates BL2 laboratory space for both process development and quality control testing.

Lonza Houston, Inc. has access to several proprietary production, purification and formulation processes for the development and manufacturing of viral-based products.  In addition, our viral facility maintains access to the PerC6® cell line and the newly formulated Permexcis® cell culture medium for optimal virus production.